Suvro Sankha Datta: IVIG-Induced Hemolysis and the Role of ABO Antibodies
Suvro Sankha Datta, Senior Consultant and Head Transfusion Medicine at Tata Medical Center, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
“IVIG is generally considered a safe product.
However, IVIG-induced hemolysis is increasingly reported in non-O blood group patients, particularly in children and in the presence of underlying inflammatory conditions.
IVIG contains ABO antibodies (IgG2 type), but the level of ABO antibodies is not provided by manufacturers, which should be below 1:64 according to the international guidelines.
The standard hemagglutination technique is not suitable for ABO antibody estimation in IVIG; therefore, the new bead-based glycan assay measuring ABO antibodies, including their subclasses, should be used as part of manufacturer quality control for commercially available IVIG products. The final titer value should be displayed over the product label.”
Title: Impact of ABO antibody components in Intravenous Immunoglobulin products on transfusion decision-making for patients following autologous stem cell transplantation
Authors: Najla Haneefa Basheela, Aniruddha Hazra, Durba Biswas, Debapriya Basu, Suvro Sankha Datta
Read the Full Article on Indian Journal of Hematology and Blood Transfusion

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines